AstraZeneca Receives “Reduce” Rating from Swedbank (AZN)
AstraZeneca (LON:AZN)‘s stock had its “reduce” rating restated by research analysts at Swedbank in a report released on Monday, American Banking News.com reports. They currently have a GBX 3,378.87 ($55.46) target price on the stock. Swedbank’s price objective would suggest a potential downside of 13.80% from the stock’s previous close.
AZN has been the subject of a number of other recent research reports. Analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca in a research note to investors on Friday. They now have a GBX 3,300 ($54.17) price target on the stock. Separately, analysts at Panmure Gordon raised their price target on shares of AstraZeneca from GBX 3,200 ($52.53) to GBX 3,500 ($57.45) in a research note to investors on Thursday. They now have a “sell” rating on the stock. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,220 ($52.86) price target on the stock. Twelve research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 3,358.68 ($55.13).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.